Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer

February 24, 2026 - 18:27

SUNRISE, Fla., Feb. 24, 2026 – Transpire Bio Inc., a clinical-stage biopharmaceutical firm dedicated to creating inhaled therapeutics for pulmonary and systemic conditions, has announced the strategic appointment of R. LaDuane Clifton as its new Chief Financial Officer. This move signals a pivotal step in the company's evolution.

The appointment comes as Transpire Bio advances its pipeline of innovative inhaled therapies, positioning itself for a transition toward commercialization. Clifton brings extensive financial leadership experience in the life sciences sector, with a proven track record in corporate finance, strategic transactions, and guiding companies through critical growth phases.

Dr. Xian-Ming Zeng, Chief Executive Officer of Transpire Bio, commented on the strategic hire, stating, "As we continue to progress from a clinical-stage to a commercial-stage biopharmaceutical company, we are aligning our leadership structure to support the next phase of our growth. LaDuane's deep expertise in financial strategy and capital markets will be invaluable as we execute on our mission to bring transformative inhaled treatments to patients."

In his new role, Clifton will oversee all financial operations, including corporate strategy, financial planning, investor relations, and capital allocation. His leadership is expected to be instrumental in building the financial infrastructure required to support Transpire Bio's expanding research and development programs and future commercial initiatives. The company is focused on addressing significant unmet medical needs through its proprietary inhalation technology platform.